Roche Holding, CH1499059983

Roche Holding stock: FDA approves Wilserdly for advanced breast cancer

Published on 11/19/2026 at 17:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock is in focus after U.S. regulators cleared Wilserdly for advanced breast cancer. A second review could broaden its reach.

Regulatory progress and trading context

  • The FDA cleared Wilserdly with everolimus for a defined group of patients with advanced breast cancer.
  • Roche is awaiting a further U.S. review that could extend the treatment to earlier-stage disease.
  • The latest Lang & Schwarz quote was below the level cited in the previous Roche Holding coverage.
Roche Holding, CH1499059983, Illustration mit AI erstellt.

On November 16, the U.S. Food and Drug Administration approved Roche's Wilserdly in combination with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. Roche announced the decision in an investor update.

FDA approval targets treatment resistance

The approval covers patients whose disease returned during or after endocrine-based adjuvant therapy or progressed after at least one endocrine-based regimen in the metastatic setting. The treatment combines the oral selective estrogen receptor degrader giredestrant with everolimus.

Roche said the phase III evERA study supported the decision. In patients with ESR1-mutated disease previously treated with a CDK4/6 inhibitor, the combination reduced the risk of disease progression or death by 62 percent compared with standard endocrine therapy plus everolimus. The reported stratified hazard ratio was 0.38.

Next regulatory checkpoint

Wilserdly is also under review for adjuvant treatment in adults with ER-positive, HER2-negative stage I, II and III breast cancer at intermediate to high risk of recurrence. The FDA has set November 30, 2026, as the Prescription Drug User Fee Act date for that application. A positive decision would extend the medicine into earlier-stage disease.

Trading context for investors

Roche Holding stock traded at 432.05 euros on Lang & Schwarz at 17:43 CET on Thursday, November 19, 2026. Compared with the 436.55-euro quote cited at 18:00 CET on Wednesday, November 18, the stock was down 1.03 percent. The move provides a separate near-term market reference as investors assess the regulatory pipeline.

Roche Holding at a glance

  • Company: Roche Holding AG
  • ISIN: CH1499059983
  • Trading venue: Lang & Schwarz
  • Quote: 432.05 euros on Thursday, November 19, 2026, at 17:43 CET
  • Regulatory event: FDA approval of Wilserdly with everolimus announced on November 16, 2026

Swiss equity coverage and broader market developments are available in Current market reports.

More news and analyses on Roche Holding stock

Disclaimer...
en | CH1499059983 | ROCHE HOLDING | boerse | 70537364 | bgmi